17
NEWS
Global experiences and personal narratives on
diabetes technology and access article as included in
the June 2024 issue of the publication Diabetologia. To
read it in full, either click the pic to download a PDF,
or to read online, click HERE.
Tirzepatide tackles T2D
Researchers at the University of Liverpool have found
that the weight loss drug, Tirzepatide is associated
with significantly reduced risk of developing Type 2
diabetes (T2D).
Obesity is a major worldwide health concern. Current
global estimates of the number of adults living with
obesity is at 650m, with a further 340m children and
adolescents. Overweight and obesity represent the
primary risk factors for the development of T2D, with T2D
driving excess morbidity and mortality.
The study published in The Lancet's eClinicalMedicine
used anonymised electronic medical records from a global
federated database. Two cohorts of individuals were
generated from this data; group one was those without
pre-existing T2D, the second with T2D. Using real world
data, Tirzepatide was tested in comparison to another
weight loss drug, Semaglutide. Compared to Semaglutide,
Tirzepatide was found to be associated with significantly
reduced risk of developing T2D in people living with
obesity, and a reduction in major adverse cardiovascular
events in people with T2D.
To find out more, CLICK HERE
Uni's AI sight
technology
The University of Liverpool's AI diagnostic
technology spin-out, AI-Sight, has successfully
concluded its seven-figure equity funding round
from experienced healthcare industry figures and
investors.
The funders, committed to developing
innovation and business in the North West of
England, include Sir Michael Bibby (Chairman of
the Bibby Line Group and Hon PhD, University of
Liverpool), Phil Kirby (former Managing Director
of InHealth Intelligence), Pitalia Capital (the family
office of Anil Pitalia, Founder of SpaMedica) and
Deepbridge Capital.
The round closure follows the Class 1 medical
device certification of AI-Sight's first commercial
product, an AI software device designed to support
training and diagnostic decision-making by human
graders of diabetic retinopathy in retinal scans.
AI-Sight has also signed a research collaboration
agreement with the UK's largest specialist provider
of diagnostic and healthcare solutions, the InHealth
Group. This collaboration brings together industry
leading healthcare solutions and the deep research
and clinical experience of the AI-Sight team to
accelerate the commercial study programme.
This funding round will support MHRA
approval and Class 2 certification for AI-Sight's
full diagnostic platform and its launch in the UK
and internationally. The platform is designed to
improve patient outcomes, with additional benefits
that promote efficiency in public health systems
and ensure human resources are allocated to the
areas of greatest need.
To find out more, CLICK HERE